February 8, 2011

Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies

.   .   

This paper continues to follow patients from two randomized controlled trials comparing standard treatment with cyclosporine to a regime including belatacept, the fist costimulatory receptor blocker. Patient and graft survival were similar in both groups, with better renal function in the belatacept groups.

Related Articles:

Renal Transplantation

Comments are closed.